BioPharma Credit (BPCP) Competitors

BioPharma Credit logo
GBX 75.12 +0.92 (+1.25%)
As of 11/20/2026 12:11 PM Eastern

BPCP vs. ABDN, 3IN, BPT, ATST, and EMG

Should you buy BioPharma Credit stock or one of its competitors? BioPharma Credit's main competitors and comparable companies include abrdn (ABDN), 3i Infrastructure (3IN), Bridgepoint Group (BPT), Alliance Trust (ATST), and Man Group (EMG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "capital markets" industry.

How does BioPharma Credit compare to abrdn?

abrdn (LON:ABDN) and BioPharma Credit (LON:BPCP) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

abrdn has higher revenue and earnings than BioPharma Credit. abrdn is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
abrdn£1.36B2.82£316.36M£20.9010.25
BioPharma Credit£95.48M10.81£130.67M£6.7711.10

abrdn has a beta of 1.398, meaning that its share price is 40% more volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.176, meaning that its share price is 82% less volatile than the broader market.

abrdn presently has a consensus target price of GBX 226.50, indicating a potential upside of 5.74%. Given abrdn's stronger consensus rating and higher probable upside, analysts clearly believe abrdn is more favorable than BioPharma Credit.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
abrdn
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
BioPharma Credit
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, abrdn's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
abrdn Neutral
BioPharma Credit Neutral

abrdn pays an annual dividend of GBX 14.60 per share and has a dividend yield of 6.8%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.3%. abrdn pays out 69.9% of its earnings in the form of a dividend. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

42.1% of abrdn shares are owned by institutional investors. Comparatively, 23.7% of BioPharma Credit shares are owned by institutional investors. 0.7% of abrdn shares are owned by insiders. Comparatively, 0.1% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioPharma Credit has a net margin of 89.20% compared to abrdn's net margin of 28.07%. BioPharma Credit's return on equity of 9.39% beat abrdn's return on equity.

Company Net Margins Return on Equity Return on Assets
abrdn28.07% 7.37% 0.68%
BioPharma Credit 89.20%9.39%5.33%

Summary

abrdn beats BioPharma Credit on 10 of the 16 factors compared between the two stocks.

How does BioPharma Credit compare to 3i Infrastructure?

3i Infrastructure (LON:3IN) and BioPharma Credit (LON:BPCP) are both finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

3i Infrastructure currently has a consensus price target of GBX 450, indicating a potential upside of 12.64%. Given 3i Infrastructure's stronger consensus rating and higher probable upside, analysts clearly believe 3i Infrastructure is more favorable than BioPharma Credit.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
3i Infrastructure
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
BioPharma Credit
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

3i Infrastructure has higher revenue and earnings than BioPharma Credit. BioPharma Credit is trading at a lower price-to-earnings ratio than 3i Infrastructure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
3i Infrastructure£301M12.24£347M£32.0012.48
BioPharma Credit£95.48M10.81£130.67M£6.7711.10

3i Infrastructure has a net margin of 92.78% compared to BioPharma Credit's net margin of 89.20%. 3i Infrastructure's return on equity of 10.77% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
3i Infrastructure92.78% 10.77% 4.83%
BioPharma Credit 89.20%9.39%5.33%

3i Infrastructure has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.176, meaning that its share price is 82% less volatile than the broader market.

24.4% of 3i Infrastructure shares are owned by institutional investors. Comparatively, 23.7% of BioPharma Credit shares are owned by institutional investors. 0.1% of 3i Infrastructure shares are owned by company insiders. Comparatively, 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, 3i Infrastructure's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
3i Infrastructure Neutral
BioPharma Credit Neutral

3i Infrastructure pays an annual dividend of GBX 13.05 per share and has a dividend yield of 3.3%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.3%. 3i Infrastructure pays out 40.8% of its earnings in the form of a dividend. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

3i Infrastructure beats BioPharma Credit on 14 of the 16 factors compared between the two stocks.

How does BioPharma Credit compare to Bridgepoint Group?

Bridgepoint Group (LON:BPT) and BioPharma Credit (LON:BPCP) are both finance companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

BioPharma Credit has a net margin of 89.20% compared to Bridgepoint Group's net margin of 4.18%. BioPharma Credit's return on equity of 9.39% beat Bridgepoint Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Bridgepoint Group4.18% 2.71% 3.47%
BioPharma Credit 89.20%9.39%5.33%

Bridgepoint Group pays an annual dividend of GBX 9.40 per share and has a dividend yield of 2.4%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.3%. Bridgepoint Group pays out 313.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

Bridgepoint Group currently has a consensus price target of GBX 445, suggesting a potential upside of 15.95%. Given Bridgepoint Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Bridgepoint Group is more favorable than BioPharma Credit.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bridgepoint Group
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
BioPharma Credit
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Bridgepoint Group has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.176, meaning that its share price is 82% less volatile than the broader market.

In the previous week, Bridgepoint Group's average media sentiment score of 1.55 beat BioPharma Credit's score of 0.00 indicating that Bridgepoint Group is being referred to more favorably in the media.

Company Overall Sentiment
Bridgepoint Group Very Positive
BioPharma Credit Neutral

28.2% of Bridgepoint Group shares are owned by institutional investors. Comparatively, 23.7% of BioPharma Credit shares are owned by institutional investors. 2.1% of Bridgepoint Group shares are owned by company insiders. Comparatively, 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioPharma Credit has lower revenue, but higher earnings than Bridgepoint Group. BioPharma Credit is trading at a lower price-to-earnings ratio than Bridgepoint Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bridgepoint Group£583.70M5.94£45.58M£3.00127.93
BioPharma Credit£95.48M10.81£130.67M£6.7711.10

Summary

Bridgepoint Group beats BioPharma Credit on 9 of the 17 factors compared between the two stocks.

How does BioPharma Credit compare to Alliance Trust?

Alliance Trust (LON:ATST) and BioPharma Credit (LON:BPCP) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

6.9% of Alliance Trust shares are held by institutional investors. Comparatively, 23.7% of BioPharma Credit shares are held by institutional investors. 2.4% of Alliance Trust shares are held by company insiders. Comparatively, 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alliance Trust has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.176, indicating that its share price is 82% less volatile than the broader market.

Alliance Trust has a net margin of 92.17% compared to BioPharma Credit's net margin of 89.20%. Alliance Trust's return on equity of 17.93% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
Alliance Trust92.17% 17.93% 10.95%
BioPharma Credit 89.20%9.39%5.33%

Alliance Trust pays an annual dividend of GBX 26 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.3%. Alliance Trust pays out 1,226.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Alliance Trust's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
Alliance Trust Neutral
BioPharma Credit Neutral

Alliance Trust has higher revenue and earnings than BioPharma Credit. Alliance Trust is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alliance Trust£652.76M0.00£601.66M£2.12N/A
BioPharma Credit£95.48M10.81£130.67M£6.7711.10

Summary

Alliance Trust beats BioPharma Credit on 8 of the 12 factors compared between the two stocks.

How does BioPharma Credit compare to Man Group?

Man Group (LON:EMG) and BioPharma Credit (LON:BPCP) are both finance companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Man Group pays an annual dividend of GBX 17.02 per share and has a dividend yield of 5.7%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.3%. Man Group pays out 60.6% of its earnings in the form of a dividend. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Man Group currently has a consensus price target of GBX 358.33, suggesting a potential upside of 19.05%. Given Man Group's stronger consensus rating and higher possible upside, research analysts plainly believe Man Group is more favorable than BioPharma Credit.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Man Group
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
BioPharma Credit
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

47.9% of Man Group shares are owned by institutional investors. Comparatively, 23.7% of BioPharma Credit shares are owned by institutional investors. 7.7% of Man Group shares are owned by company insiders. Comparatively, 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Man Group has a beta of 0.631, meaning that its share price is 37% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.176, meaning that its share price is 82% less volatile than the broader market.

In the previous week, Man Group had 1 more articles in the media than BioPharma Credit. MarketBeat recorded 1 mentions for Man Group and 0 mentions for BioPharma Credit. Man Group's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
Man Group Neutral
BioPharma Credit Neutral

BioPharma Credit has a net margin of 89.20% compared to Man Group's net margin of 18.60%. Man Group's return on equity of 20.41% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
Man Group18.60% 20.41% 4.61%
BioPharma Credit 89.20%9.39%5.33%

Man Group has higher revenue and earnings than BioPharma Credit. Man Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Man Group£1.69B1.97£382.68M£28.1010.71
BioPharma Credit£95.48M10.81£130.67M£6.7711.10

Summary

Man Group beats BioPharma Credit on 12 of the 17 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCP vs. The Competition

MetricBioPharma CreditCapital Markets IndustryFinance SectorLON Exchange
Market Cap£1.31B£4.26B£12.10B£2.36B
Dividend Yield7.34%5.68%5.05%5.11%
P/E Ratio11.1023.3219.4422.78
Price / Sales10.818.295.274.91
Price / Cash98.0029.1519.7220.23
Price / Book0.761.671.712.40
Net Income£130.67M£419.50M£1.32B£5.88B
7 Day Performance-0.37%-4.23%-4.23%-3.59%
1 Month Performance2.81%-4.26%-4.45%-3.91%
1 Year Performance11.46%-4.18%2.12%5.17%

BioPharma Credit Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCP
BioPharma Credit
N/AGBX 75.12
+1.2%
N/A+11.5%£1.31B£95.48M11.10N/A
ABDN
abrdn
N/AGBX 228.40
-0.5%
GBX 226.50
-0.8%
+10.0%£4.09B£1.71B10.934,719
3IN
3i Infrastructure
N/AGBX 409.50
+0.1%
GBX 450
+9.9%
+13.3%£3.78B£301M12.80N/A
BPT
Bridgepoint Group
2.3783 of 5 stars
GBX 407
-2.4%
GBX 445
+9.3%
+40.9%£3.68B£583.70M135.67391
ATST
Alliance Trust
N/AN/AN/AN/A£3.58B£652.76M600.003

Related Companies and Tools


This page (LON:BPCP) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners